FDA Clears Roxicet for Generic Copies, No Safety Snags
Published Date: 8/4/2025
Notice
Summary
The FDA says ROXICET tablets (5 mg oxycodone and 325 mg acetaminophen) weren’t pulled from the market because of safety or effectiveness problems. This means drug companies can now apply to sell generic versions, as long as they follow the rules. Patients and pharmacies could see more affordable options soon, with no safety worries slowing things down.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Generic Approval Pathway Opens
The FDA determined that ROXICET (oxycodone hydrochloride and acetaminophen) tablet, 5 mg/325 mg, was not withdrawn for reasons of safety or effectiveness. Because of this, the FDA can approve abbreviated new drug applications (ANDAs) for the 5 mg/325 mg tablet if all other legal and regulatory requirements are met.
Patients and Pharmacies May See Cheaper Options
Because FDA can now approve ANDAs for the oxycodone HCl and acetaminophen 5 mg/325 mg tablet, patients who use that medicine and pharmacies could see more affordable generic options become available. The approval pathway is allowed only if all other legal and regulatory requirements are met.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-16959, Frequently Asked Questions-Developing Potential Cellular and Gene Therapy Products; Final Guidance for Industry; Availability
The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance titled "Frequently asked Questions--Developing Potential Cellular and Gene Therapy Products." The guidance document provides industry with answers to frequently asked questions (FAQs) and commonly faced issues that arise during the development of cellular and gene therapy (CGT) products. The FAQs represent common questions directed to the Agency and span multiple disciplines, including regulatory review; chemistry, manufacturing, and controls (CMC); pharmacology/toxicology; clinical; and clinical pharmacology. This guidance announced in this notice finalizes the draft guidance of the same title issued on November 19, 2024.
2026-16944, Gardenia Blue Interest Group; Filing of Color Additive Petition
The Food and Drug Administration (FDA or we) is announcing that we have filed a petition, submitted by Gardenia Blue Interest Group (GBIG or petitioner), c/o Exponent, Inc., proposing that we amend our color additive regulations to expand the safe use of gardenia (genipin) blue in various foods at levels consistent with good manufacturing practice. The petition also proposes to lower the specification for arsenic in gardenia (genipin) blue.
2026-16942, Food Additives Permitted in Feed and Drinking Water of Animals; Chromium DL-methionine Chelate
The Food and Drug Administration (FDA, we, or the Agency) is amending the regulations for food additives permitted in feed and drinking water of animals to provide for the safe use of chromium DL- methionine chelate as a nutritional source of chromium in cattle feed. This action is in response to a food additive petition filed by Zinpro Corp.
Previous / Next Documents
Previous: 2025-14706, Agency Information Collection Activities; Proposed eCollection eComments Requested; New Collection; Title-DEA Voluntary Wellness Program Healthcare Provider Clearance
The Drug Enforcement Administration (DEA) wants to start a new voluntary wellness program for healthcare providers. They’re asking for feedback on a new form to help make this happen, aiming to support healthcare workers’ well-being without adding extra costs or big time commitments. If you’re a healthcare provider, this is your chance to weigh in before the plan moves forward!
Next: 2025-14708, Unwrought Palladium From Russia; Institution of Antidumping and Countervailing Duty Investigations and Scheduling of Preliminary Phase Investigations
The U.S. is launching investigations to see if cheap or government-supported palladium from Russia is hurting American businesses. If the claims are true, extra taxes might be added to these imports to protect U.S. companies. The first big decision is expected by September 15, 2025, so things are moving fast!